- Home
- SYBT vs AUPH Comparison
SYBT vs AUPH Comparison
Compare SYBT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYBT | AUPH |
|---|---|---|
| Founded | 1904 | 1993 |
| Country | United States | Canada |
| Employees | 1270 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2009 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SYBT | AUPH |
|---|---|---|
| Price | $78.65 | $16.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $76.00 | $17.25 |
| AVG Volume (30 Days) | 130.2K | ★ 741.3K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | 22.11 | ★ 5075.00 |
| EPS | ★ 2.55 | 0.53 |
| Revenue | $23,406,000.00 | ★ $283,055,000.00 |
| Revenue This Year | $17.31 | $17.54 |
| Revenue Next Year | $9.32 | $15.74 |
| P/E Ratio | ★ $30.61 | $31.31 |
| Revenue Growth | 3.37 | ★ 20.38 |
| 52 Week Low | $61.51 | $10.34 |
| 52 Week High | $89.22 | $19.25 |
Technical Indicators
Market Signals| Indicator | SYBT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 53.18 |
| Support Level | $77.12 | $15.65 |
| Resistance Level | $82.14 | $17.02 |
| Average True Range (ATR) | 1.71 | 0.43 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 32.88 | 51.53 |
Price Performance
Historical ComparisonAbout SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.